Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 15:18:100518.
doi: 10.1016/j.mtbio.2022.100518. eCollection 2023 Feb.

On-demand biomanufacturing through synthetic biology approach

Affiliations

On-demand biomanufacturing through synthetic biology approach

Chenwang Tang et al. Mater Today Bio. .

Abstract

Biopharmaceuticals including protein therapeutics, engineered protein-based vaccines and monoclonal antibodies, are currently the mainstay products of the biotechnology industry. However, the need for specialized equipment and refrigeration during production and distribution poses challenges for the delivery of these technologies to the field and low-resource area. With the development of synthetic biology, multiple studies rewire the cell-free system or living cells to impact the portable, on-site and on-demand manufacturing of biomolecules. Here, we review these efforts and suggest future directions.

Keywords: Biomanufacturing; Cell-free system; Engineered microorganisms; On-demand; Portability; Synthetic biology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
On-demand biomanufacturing. In this review, we summarize approaches of engineering cell-free protein synthesis (CFPS) and living cellular hosts to accomplish the on-demand biomanufacturing. Compared with conventional large-scale fermentation, on-demand biomanufacturing can be flexible and portable to meet requirements under different situations.
Fig. 2
Fig. 2
Engineering cell-free protein synthesis platform for on-demand biomanufacturing.
  1. a.

    Embedding cell-free synthetic gene networks onto papers and other materials for rapid sensing and diagnoses [25].

  2. b.

    Engineering the freeze-dried cell-free system to produce various therapeutics including antimicrobial peptides (AMPs), vaccines, combinatorial antibodies and small molecules on-site and on-demand [27].

  3. c.

    A modular technology for in vitro conjugate vaccine expression (iVAX) in a portable and on-demand fashion [28].

  4. d.

    Cell-free workflow for modular synthesis, assembly and discovery of multi-enzyme glycosylation pathways in vitro [37].

Fig. 3
Fig. 3
Engineering living cells for portable and on-demand biomanufacturing.
  1. a.

    Developing microbial swarmbot (MSB) platform that integrates the multiple steps of production, disruption and separation in a concise format [49].

  2. b.

    Engineering a temperature-responsive, shear-thinning hydrogel system to harness the bioactivity of embedded microbes for on-demand production of small molecules and peptides [50].

  3. c.

    An integrated, benchtop and portable microfluidic device containing genetically engineered P. pastoris to generate multiple therapeutic proteins [51].

  4. d.

    An automated desktop multi-product manufacturing system named InSCyT (Integrated Scalable Cyto-Technology) to integrate fermentation, sensing, input and output, purification and analysis automatically [52].

Similar articles

Cited by

References

    1. Dove A. Uncorking the biomanufacturing bottleneck. Nat. Biotechnol. 2002;20:777–779. doi: 10.1038/nbt0802-777. - DOI - PubMed
    1. Baeshen M.N., et al. Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J. Microbiol. Biotechnol. 2015;25:953–962. doi: 10.4014/jmb.1412.12079. - DOI - PubMed
    1. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014;32:992–1000. doi: 10.1038/nbt.3040. - DOI - PubMed
    1. Kalyanpur M. Downstream processing in the biotechnology industry. Mol. Biotechnol. 2002;22:87–98. doi: 10.1385/MB:22:1:087. - DOI - PubMed
    1. Jacquemart R., et al. A single-use strategy to enable manufacturing of affordable biologics. Comput. Struct. Biotechnol. J. 2016;14:309–318. doi: 10.1016/j.csbj.2016.06.007. - DOI - PMC - PubMed

LinkOut - more resources